Skip to main content

Table 1 Mean (SD) [range] administered activity, length of stay in hospital, percentage 177Lu and activity retention at discharge for outpatient and inpatient administrations

From: Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours

 

Number of administrations

Number of patients

Administered activity (MBq)

Time T0TD (h)

177Lu retention (%)

Retained activity (MBq)

Inpatients

32

16

7079 (419)

[5925–7890]

18.1 (1.5)

[16.2–21.2]

36 (15)

[15–62]

2537 (1079)

[1087–4482]

177Lu-DOTATATE Mallinckrodt

Inpatients

24

18

7545 (204)

[7076–7913]

18.2 (1.1)

[16.7–21.0]

24 (7)

[13–37]

1806 (494)

[984–2740]

 Lutathera® AAA

Outpatients

20

15

7608 (242)

[7259–8038]

5.2 (0.7)

[3.6–6.3]

38 (8)

[28–58]

2897 (663)

[2103–4670]

 Lutathera® AAA